QRG Capital Management Inc. Sells 31,921 Shares of Twist Bioscience Co. (NASDAQ:TWST)

QRG Capital Management Inc. decreased its position in Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 53.7% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 27,522 shares of the company's stock after selling 31,921 shares during the quarter. QRG Capital Management Inc.'s holdings in Twist Bioscience were worth $1,243,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of TWST. Signaturefd LLC lifted its position in Twist Bioscience by 63.0% in the third quarter. Signaturefd LLC now owns 792 shares of the company's stock worth $36,000 after purchasing an additional 306 shares during the period. EdgeRock Capital LLC acquired a new position in Twist Bioscience in the 2nd quarter valued at approximately $43,000. Blue Trust Inc. grew its stake in Twist Bioscience by 2,912.8% in the second quarter. Blue Trust Inc. now owns 1,175 shares of the company's stock valued at $58,000 after purchasing an additional 1,136 shares in the last quarter. DekaBank Deutsche Girozentrale bought a new position in Twist Bioscience during the second quarter valued at approximately $61,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Twist Bioscience by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company's stock worth $98,000 after purchasing an additional 381 shares in the last quarter.

Wall Street Analysts Forecast Growth

TWST has been the topic of a number of research analyst reports. Leerink Partners raised their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a "market perform" rating in a research note on Thursday, October 17th. Evercore ISI upped their price target on Twist Bioscience from $52.00 to $56.00 and gave the company an "outperform" rating in a research note on Tuesday, October 1st. Robert W. Baird lifted their price target on Twist Bioscience from $40.00 to $46.00 and gave the company an "outperform" rating in a research note on Monday, August 5th. Barclays dropped their price target on shares of Twist Bioscience from $60.00 to $55.00 and set an "overweight" rating on the stock in a research report on Monday, August 5th. Finally, JPMorgan Chase & Co. raised their price target on Twist Bioscience from $28.00 to $35.00 and gave the stock an "underweight" rating in a research report on Monday, August 5th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $51.22.

Insider Buying and Selling

In other news, CEO Emily M. Leproust sold 14,334 shares of the firm's stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $44.60, for a total transaction of $639,296.40. Following the completion of the sale, the chief executive officer now directly owns 589,552 shares of the company's stock, valued at $26,294,019.20. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other Twist Bioscience news, CAO Robert F. Werner sold 1,448 shares of the business's stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total value of $64,580.80. Following the completion of the transaction, the chief accounting officer now owns 45,620 shares of the company's stock, valued at $2,034,652. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Emily M. Leproust sold 14,334 shares of the stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total transaction of $639,296.40. Following the transaction, the chief executive officer now directly owns 589,552 shares in the company, valued at approximately $26,294,019.20. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 73,356 shares of company stock worth $3,205,239. 3.92% of the stock is owned by insiders.

Twist Bioscience Stock Down 0.3 %

TWST stock traded down $0.12 during midday trading on Friday, reaching $45.40. 638,602 shares of the company's stock traded hands, compared to its average volume of 941,083. The company has a market cap of $2.66 billion, a price-to-earnings ratio of -11.88 and a beta of 1.78. The firm's fifty day moving average price is $43.69 and its 200-day moving average price is $45.54. Twist Bioscience Co. has a 52 week low of $15.85 and a 52 week high of $60.90.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.